Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Deferred Taxes (2021 - 2025)

Kiniksa Pharmaceuticals International's Deferred Taxes history spans 5 years, with the latest figure at $3.1 million for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 199.21% year-over-year to $3.1 million; the TTM value through Dec 2025 reached $13.0 million, up 59.89%, while the annual FY2025 figure was $13.0 million, 59.89% up from the prior year.
  • Deferred Taxes reached $3.1 million in Q4 2025 per KNSA's latest filing, down from $4.2 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $10.6 million in Q2 2024 to a low of -$25.7 million in Q4 2023.
  • Average Deferred Taxes over 5 years is -$878285.7, with a median of $1.9 million recorded in 2023.
  • Peak YoY movement for Deferred Taxes: crashed 7487.64% in 2023, then skyrocketed 305.29% in 2024.
  • A 5-year view of Deferred Taxes shows it stood at $10000.0 in 2021, then skyrocketed by 3380.0% to $348000.0 in 2022, then plummeted by 7487.64% to -$25.7 million in 2023, then soared by 87.7% to -$3.2 million in 2024, then skyrocketed by 199.21% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Deferred Taxes are $3.1 million (Q4 2025), $4.2 million (Q3 2025), and $2.6 million (Q2 2025).